雾化吸入溴化异丙托品、布地奈德在慢性阻塞性肺疾病急性加重期治疗中的应用

目的:探讨氧启动雾化吸入溴化异丙托品、普米克令舒在慢性阻塞性肺疾病急性加重期(AECOPD)治疗中的效果。方法:选取慢性阻塞性肺疾病急性加重期(AECOPD)患者68例,随机分为A、B、C三个方案组,用氧启动雾化吸入治疗,A组21例药物配伍为0.025%溴化异丙托品溶液(爱全乐溶液)2ml加生理盐水2ml雾化吸入,B组23例布地奈德(普米克令舒)2ml加生理盐水2ml雾化吸入,C组24例溴化异丙托品溶液(爱全乐溶液)2ml加布地奈德(普米克令舒)2ml雾化吸入,观察记录雾化吸入前和雾化吸入后72hFVC和FEV1,雾化吸入药物前后进行血气分析,同时观察不良反应及临床疗效评定。结果:在三组中,A临床症状改善有效率为66.67%,B组有效率为65.53%,C组有效率为91.67%,三组疗效比较,C组较A组和B组对照,有显著差异(P<0.05),三组用药后肺功能测定FEV1,FEV1%和FVC均有明显改善,C组较A组和B组改善更明显(P<0.05);血气分析用药前后各组间无明显差异,三组均未见明显不良反应。结论:在慢性阻塞性肺疾病急性加重期患者的治疗中,采用氧启动雾化联合吸入溴化异丙托品、布地奈德效果更好。

Efficacy of Impratropium Bromide and Budesonide incombination for the Treatment of Chronic Obstructive Pulmonary Disease at the Stage of Acute Exacerbation

Objective: To appraise the efficacy of impratropium bromide and budesonide incombination for the treatment of chronic obstructive pulmonary disease at the stage of acute exacerbation by oxygen startup atonmization inhalation. Method: 68 cases with acute exacerbation of COPD were randomized into 3 groups.Each group received 2.0ml of inhaled 0.025% impratropium bromide, 2ml budesonide or 2.0ml of inhaled 0.025% impratropium bromide plus 2ml budesonide by oxygen startup atomization inhalation. Lung function and blood gas analysis were assessed before drug administration and thereafter.Result: The effective rate of group C was significantly higher than those of group A and B;All three groups significantly improved in FEV1,FEV1% and FVC. Combination treatment with impratropium bromide and budesonide provided significantly (P<0.05) greater improvements in pulmonary function than Impratropium bromide or Budesonide given alone. Conclusion: Patients with acute exacerbation of COPD may benefit from combination treatment with Impratropium bromide and Budesonide by oxygen startup.